Study to Evaluate the Safety, Tolerability, Pharmacokinetics, & Antiviral

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01740791
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 1
Start date	November 6, 2012
Completion date	January 24, 2014

See also
	Status	Clinical Trial	Phase
	Withdrawn	`NCT02806362` - Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)	Phase 3
	Withdrawn	`NCT01691235` - SIMpill Medication Dispensing Device in the Treatment of HCV	N/A
	Completed	`NCT01701401` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV	Phase 3
	Completed	`NCT02945228` - Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
	Completed	`NCT01726517` - Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects	Phase 2
	Recruiting	`NCT05904470` - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV	Phase 2
	Completed	`NCT01851330` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)	Phase 3
	Completed	`NCT01852604` - Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)	Phase 2
	Completed	`NCT02105467` - Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)	Phase 3
	Recruiting	`NCT02038387` - Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)	N/A
	Completed	`NCT01581138` - VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C	Phase 2
	Completed	`NCT02629172` - Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
	Completed	`NCT01768286` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection	Phase 3
	Completed	`NCT01686789` - Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4	Phase 4
	Completed	`NCT00610597` - Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease	N/A
	Completed	`NCT02707952` - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection	Phase 3
	Completed	`NCT01516918` - A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis	Phase 2
	Completed	`NCT02723084` - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection	Phase 3